Occurrence of Corneal Staining after Cataract Surgery with and without Chitosan-N-Acetylcysteine Eye Drops

Ophthalmic Res. 2023;66(1):1293-1299. doi: 10.1159/000534291. Epub 2023 Oct 5.

Abstract

Introduction: The objective of this study was to evaluate the prevalence of ocular surface damage assessed by corneal staining scores right after cataract surgery and whether it can be prevented using chitosan-N-acetylcysteine (C-NAC) eye drops.

Methods: We included patients scheduled for routine cataract surgery. Each patient was randomly assigned to one of three groups. Patients in group 1 underwent routine cataract surgery with no additional eye drops. In group 2, patients received C-NAC eye drops after cataract surgery, and in group 3, C-NAC was applied both before and after surgery. Both groups continued the treatment once daily for 4 days. Ocular surface alteration was assessed using the National Eye Institute (NEI) score, and the visual analog scale (VAS) was used to evaluate subjective complaints.

Results: Thirty-six patients were included in the final analyses. One hour after cataract surgery, a statistically significant increase in corneal fluorescein staining was observed in all groups, which decreased again after 1 week. There was no significant difference between the groups 1 h after cataract surgery, though a tendency toward lower NEI scores was observed during this time point in group 3.

Discussion: Cataract surgery induced ocular surface staining and subjective complaints after 1 h. However, the increase in VAS score was small and probably not clinically relevant. The application of perioperative C-NAC eye drops did reduce the rate of corneal staining after cataract surgery in a clinically relevant manner.

Keywords: Cataract surgery; Chitosan-N-acetylcysteine; Corneal staining.

MeSH terms

  • Acetylcysteine / pharmacology
  • Acetylcysteine / therapeutic use
  • Cataract Extraction* / adverse effects
  • Cataract*
  • Chitosan*
  • Dry Eye Syndromes*
  • Humans
  • Ophthalmic Solutions

Substances

  • Ophthalmic Solutions
  • Acetylcysteine
  • Chitosan

Grants and funding

This work was supported by Croma-Pharma GmbH, and a restricted research grant is gratefully acknowledged.